Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of THVD-201, a Combination of Tolterodine and a Muscarinic Agonist vs. Tolterodine Alone vs. Placebo to measure the tolerability in Subjects with Overactive Bladder (OAB) Symptoms (Protocol No.: THVD-201-002).

Next Previous
Trial Profile

Comparison of THVD-201, a Combination of Tolterodine and a Muscarinic Agonist vs. Tolterodine Alone vs. Placebo to measure the tolerability in Subjects with Overactive Bladder (OAB) Symptoms (Protocol No.: THVD-201-002).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolterodine/pilocarpine (Primary) ; Tolterodine
  • Indications Overactive bladder; Urge incontinence
  • Focus Therapeutic Use

Most Recent Events

  • 04 Apr 2013 Status changed from recruiting to completed according to a TheraVida media release.
  • 02 Apr 2013 Results published in a TheraVida Media Release.
  • 19 Mar 2013 Results presented at the 28th Congress of the European Association of Urology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top